Publications

Our succes in integrating information into models that generate unique insights, allowing executives to make better drug development decisions, is reflected in our gold-standard research publications.

Latest publications

Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients | Infectious diseases

Prohn M et al. | qP contributors: Prohn M | 2021| Journal| Clinical Pharmacology and Therapeutics Link

Population Pharmacokinetics of Letermovir Following Oral and Intravenous Administration in Healthy Participants and Allogeneic Hematopoietic Cell Transplantation Recipients | Infectious diseases

Prohn M et al. | qP contributors: Prohn M | 2021| Journal| CPT: Pharmacometrics & Systems Pharmacology Link

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII | Haematology

Jonsson F et al. | qP contributors: Jonsson F | 2021| Journal| Clinical Pharmacokinetics Link

Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: a semi-mechanistic autoinduction model | Oncology

Krishnatry AS et al. | qP contributors: Krishnatry AS; Völkner A; Prohn M | 2021| Journal| CPT: Pharmacometrics & Systems Pharmacology Link

Design and conduct considerations for studies in patients with impaired renal function | All

Ravenstijn P et al. | qP contributors: Ravenstijn P | 2021| Journal| Clinical and Translational Science Link

Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis | Ophthalmology

Luu KT et al. | qP contributors: Green M | 2021| Journal| Journal of Clinical Pharmacology Link

Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors | Oncology

Krishnatry AS et al. | qP contributors: Krishnatry AS; Hanze E; Bergsma T; Prohn M | 2021| Journal| CPT: Pharmacometrics & Systems Pharmacology Link

SAGE-217: A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies | CNS

Hoffmann E et al. | qP contributors: Wald J | 2020| Journal| Clinical Pharmacokinetics Link

A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) With Poor Prognosis Features | Oncology

Sarkozy C et al. | qP contributors: Suttle B | 2020| Journal| Clinical Cancer Research Link

Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis | Immunology

Chan P et al. | qP contributors: Prohn M, Huisman J, Matzuka B | 2020| Journal| Pharmaceutical Research Link
Get in touch
Mail
Phone (US)
+1 919 6519713
Phone (EU)
+46 70722 90 35
Connect with us